[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-colorectal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-colorectal":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,69,96,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100483600","blood-screening-for-adult-colorectal-cancer-100483600",false,"NCT05577143","Blood Screening for Adult Colorectal Cancer","Evaluation of the Discriminatory Role of Blood TFPI-1 and TFPI-2 in Adult Colorectal Cancer","BACCHUS","Inclusion Criteria:\n\n* Patients with suspected colorectal cancer for which colonoscopy is indicated.\n* Patients between 50 and 75 years old, asymptomatic from the digestive point of view (for example referred for colonoscopy as part of a pre-operative check-up of an inguinal hernia or 3 months after an episode of complicated sigmoiditis), for whom a follow-up colonoscopy is indicated.\n\nNote.\n\n* If the post-inclusion colonoscopy is normal, no biopsy will be performed and patients will be assigned to the control group.\n* If the colonoscopy performed after inclusion is abnormal (presence of at least one mucosal lesion), patients will be assigned to the \"colorectal cancer\" group or to the \"polyps\" group depending on the results of the anatomopathological analysis of the lesion(s)\n\nExclusion Criteria:\n\n* All clinical situations outside of CRC that could increase TFPI-1 or 2 blood levels: acute coronary syndrome (unstable angina, acute myocardial infarction), severe sepsis, decompensated cirrhosis, pregnancy, chronic inflammatory bowel disease (Crohn's or ulcerative colitis), colitis or radiation rectitis.\n* Endoscopic polypectomy without prior histological confirmation.\n* Emergency (occlusion or peritonitis)\n* Minor patients.\n* Persons of full age under legal protection or unable to express their consent\n* Persons not affiliated to a social security system or beneficiaries of such a system.\n* Pregnant women, women in labor or nursing mothers.","ALL","18 Years","75 Years",{"count":21,"type":22},303,"ESTIMATED","OBSERVATIONAL","Multicenter, inter-regional, case-control study with the primary objective of evaluating the discriminative power of the blood biomarker TFPI-1 to separate patients with histologically proven CRC from an asymptomatic control population between 50 and 75 years of age with normal colonoscopy.",[26],"Cancer Colorectal",[28,29],"Oncology","Biology","RECRUITING","2026-05-20",{"date":33,"type":34},"2026-05-22","ACTUAL",{"date":36,"type":34},"2023-03-23",{"date":38,"type":22},"2027-03",{"name":40,"class":41},"University Hospital, Lille","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100599941","building-connections-100599941","NCT07091032","Building Connections","Building Connections Between Practices, Patients, and Community Health","Inclusion Criteria:\n\n* The general inclusion criteria involve being 18+, speaking English or Spanish, and meeting one or more of the following criteria:\n\nObesity: Patients with a body mass index of 30 kg\u002Fm2 or greater (i.e., obese category).\n\nCancer screening: Average-risk patients without recommended colorectal or cervical cancer screenings for their age group and biological sex. Specifically:\n\nColon Cancer (CRC) inclusion criteria: Patients aged 45-75 who are due for screenings, with last FIT longer than 1 year ago, last colonoscopy longer than 10 years ago, and last Cologuard longer than 3 years ago.\n\nAnd\u002For\n\nCervical cancer inclusion criteria: Women and patients with a cervix aged 30-65 who are due for screening: with last pap longer than 3 years ago; last co-test longer than 5 years ago; last primary HPV screening longer than 5 years ago.\n\nMental health: Patients with moderate to severe depression or anxiety symptoms.\n\nExclusion Criteria:\n\n* The general exclusion criteria are: those with current pregnancy, or the participant is cognitively impaired, not having a visit to the primary care clinic in the prior 2 years, and speaking a language other than English or Spanish.\n\nExclusion criteria for obesity intervention: had prior metabolic or bariatric surgery or planning to have this surgery in the next 6 months, currently enrolled in an intensive lifestyle program.\n\nExclusion criteria for cancer screening intervention include:\n\nColon Cancer (CRC) exclusion criteria: has colorectal cancer documented in the problem list; has ulcerative colitis or Crohn's disease documented in the problem list\n\nCervical cancer exclusion criteria: has cervical cancer documented in the problem list; has had a prior hysterectomy.\n\nExclusion criteria for mental health: include patients with active suicidality, active substance use disorder, a history of schizophrenia or bipolar disorder, or who are already receiving behavioral health care (therapy sessions in the past 3 months or an appointment upcoming in the next month).",{"count":51,"type":22},3600,"INTERVENTIONAL",[54],"NA","Building Connections seeks to address health and healthcare inequities in socially vulnerable communities. The project will be conducted in collaboration with clinical practices across Massachusetts, serving a diverse population heavily represented in Community Clinics and Health Centers. The program will offer evidence-based interventions in obesity\u002Fweight management, cancer screening, and mental health.",[26,57,58,59],"Cancer Cervix","Depression, Anxiety","Obesity","2025-11-17",{"date":62,"type":34},"2025-11-18",{"date":64,"type":34},"2025-08-07",{"date":66,"type":22},"2029-12-30",{"name":68,"class":41},"Massachusetts General Hospital",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100407943","french-colorectal-esd-cohort-in-experts-centers-100407943","NCT04592003","French Colorectal ESD Cohort in Experts Centers","FECCo","Inclusion Criteria:\n\nAll patients addressed for a colorectal ESD\n\nExclusion Criteria:\n\nOpposition notified in the context of a non-opposition form after reading the information notice",{"count":77,"type":22},1200,"Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR.\n\nScientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures.\n\nA lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions.\n\nThe aim of this French multicenter cohort is to analyze the results of colorectal submucosal dissection on a large scale.",[26,80,81],"Polyps Colorectal","Endoscopic Submucosal Resection",[83,84,85],"Cancer colorectal","Polyps colorectal","Endoscopic submucosal resection","2025-09-08",{"date":88,"type":34},"2025-09-15",{"date":90,"type":34},"2020-01-01",{"date":92,"type":22},"2026-01-01",{"name":94,"class":41},"University Hospital, Limoges",25,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":105,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":42},"100480446","ctdna-methylation-application-in-postoperative-relapse-and-adjuvant-chemotherapy-efficacy-evaluation-100480446","NCT05536089","ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation","ctDNA Methylation Used to Monitor Postoperative Relapse and Evaluate Adjuvant Chemotherapy Efficacy in Resected Stage I and Stage II (Without High Risk) Colorectal Cancer After Radical Resection","Inclusion Criteria:\n\n* Patients must have histologically confirmed stage I\u002FII (without high risk) colorectal cancer.\n* Male or female ≥ 18 years of age on the day of signing informed consent.\n* Patients need to receive surgical resection, and with ctDNA positive prior to resection of colorectal cancer (CRC).\n* Patients must have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.\n* Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Personal history of colorectal cancer, colorectal adenoma or aerodigestive tract cancer.\n* Induction of neoadjuvant systemic therapy prior to resection of CRC.\n* Patient is pregnant or lactating.\n* Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Investigator.\n* Inadequate tumor material (either quality and quantity) to support circulating tumor DNA (ctDNA) analysis.",{"count":104,"type":22},2000,"5 Years","In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in resected stage I and stage II (without high risk) colorectal cancer after radical resection.",[26],[109],"early detection","2024-05-21",{"date":112,"type":34},"2024-05-22",{"date":114,"type":34},"2022-09-05",{"date":116,"type":22},"2028-12",{"name":118,"class":119},"Singlera Genomics Inc.","INDUSTRY",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":52,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100533880","digital-home-based-prehabilitation-before-surgery-100533880","NCT06231576","Digital Home-Based Prehabilitation Before Surgery","dHOPE","Inclusion Criteria:\n\n* Planned for major gastrointestinal cancer surgery\n* Fluent in Norwegian and able to consent and to understand questionnaires\n\nExclusion Criteria:\n\n* Inability to walk for six minutes or to rise independently from a chair\n* Inability to comprehend exercise program or to comply with written and oral instructions\n* Presence of a cardio-pulmonary condition that precludes exercise\n* Living in very remote areas making a hospital-based intervention group impossible to implement\n* Being without a permanent address\n* Admittance to a hospital facility for \\> 50% of the time from diagnosis to surgery",{"count":128,"type":22},140,[54],"This clinical trial compares two different prehabilitation programs, with no organized prehabilitation, prior to major colorectal cancer surgery. The prehabilitation programs include intensive and coached physical exercise and optimized nutritional intake coupled with smoking cessation, physiological support and correction of poly-pharmacy.",[26,132,133],"Frailty","Surgery",[135,136,132],"Prehabilitation","Colorectal cancer","NOT_YET_RECRUITING","2024-01-26",{"date":140,"type":34},"2024-01-30",{"date":142,"type":22},"2024-02-01",{"date":144,"type":22},"2030-12-31",{"name":146,"class":41},"Vestre Viken Hospital Trust","Cancer, Colorectal"]